Passage Bio (PASG) Stock Statistics & Valuation Metrics

Passage Bio has a market cap or net worth of $31.17M. The enterprise value is -$2.91M.

Passage Bio has 3,120,295 shares outstanding. The number of shares has decreased by -2.65% in one year.

Passage Bio’s return on equity (ROE) is -1.06 and return on invested capital (ROIC) is -81.16%.

The current PE Ratio of Passage Bio is ―. Passage Bio’s PEG ratio is 0.01.

In the last 12 months, Passage Bio had revenue of 0.00 and earned -64.77M in profits. Earnings per share was -21.44.

In the last 12 months, operating cash flow was -33.47M and capital expenditures -14.00K, giving a free cash flow of -33.49M billion.

Passage Bio pays an annual dividend of ―, resulting in a dividend yield of ―

Passage Bio upcoming earnings date is Mar 9, 2026, Before Open (Confirmed).

Passage Bio as a current ratio of 4.07, with Debt / Equity ratio of 64.64%

In the past 12 months, Passage Bio has paid 0.00 in taxes.

Passage Bio EV to EBITDA ratio is -0.36, with an EV/FCF ratio of -0.46.

Passage Bio has $52.77M in cash and marketable securities with $24.34M in debt, giving a net cash position of $28.44M billion.

Gross margin is 12.61%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Passage Bio is $40.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy